RESUMO
OBJECTIVES: To compare the efficacy of azithromycin versus doxycycline in treatment of children with uncomplicated scrub typhus in terms of percentage of children who attained remission of fever after 72 hours of administration of first dose of the study drug, mean time taken to attain fever defervescence, normalization of laboratory parameters, resolution of hepatosplenomegaly and lymphadenopathy. DESIGN: Interventional, open-labeled randomized controlled trial. STUDY METHODS: Patients admitted with undifferentiated fever in the In-Patient Department (IPD), Department of Paediatrics, All India Institute of Medical Sciences, Bhubaneswar, India, as per the inclusion criteria were randomized and was treated with azithromycin at 10 mg/kg/d in one group and doxycycline at 4.4 mg/kg/d for 5 days in the other group and was assessed based on the primary and secondary objectives. RESULTS: There was no statistically significant difference between the percentage of children who attained remission of fever after 72 hours of administration of azithromycin (98.2%) and doxycycline (96.5%) (P value 0.47) and the average time taken for fever defervescence (azithromycin: 24.53 hours; doxycycline: 25.82 hours; P value 0.36). The odds of attaining fever remission in the doxycycline group as compared with the azithromycin group was 1.01 (95% confidence interval -0.60 to -1.71), which was also statistically not significant. There was less incidence of adverse drug events in the azithromycin group (1.78%) as compared with the doxycycline group (8.6%), which was statistically significant (P value 0.02). CONCLUSION: Azithromycin is equally efficacious in terms of fever defervescence, resolution of clinical signs and laboratory parameters as doxycycline, is safer and better tolerated in children.
Assuntos
Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Doxiciclina/uso terapêutico , Tifo por Ácaros/tratamento farmacológico , Pré-Escolar , Feminino , Febre/tratamento farmacológico , Humanos , Índia , Lactente , Masculino , Orientia tsutsugamushi , Infecções por Rickettsiaceae/tratamento farmacológico , Tifo por Ácaros/diagnóstico , Tifo por Ácaros/fisiopatologia , Resultado do Tratamento , Doenças Transmitidas por Vetores/tratamento farmacológicoRESUMO
Borrelia yangtzensis has been identified in rodents and ticks in China and Japan. A 57-year-old woman with bite mark was diagnosed with B. yangtzensis infection via molecular and serological testing. Here, we report the first case of human infection caused by B. yangtzensis in Korea.
Assuntos
Borrelia , Animais , Borrelia/genética , Borrelia/isolamento & purificação , DNA Bacteriano/análise , Reservatórios de Doenças/microbiologia , Doxiciclina/farmacologia , Feminino , Humanos , Doença de Lyme/microbiologia , Pessoa de Meia-Idade , República da Coreia/epidemiologia , Roedores/microbiologia , Carrapatos/microbiologia , Doenças Transmitidas por Vetores/diagnóstico , Doenças Transmitidas por Vetores/tratamento farmacológicoRESUMO
Pathogenic mosquito-borne viruses are a serious public health issue in tropical and subtropical regions and are increasingly becoming a problem in other climate zones. Drug repositioning is a rapid, pharmaco-economic approach that can be used to identify compounds that target these neglected tropical diseases. We have applied a computational drug repositioning method to five mosquito-borne viral infections: dengue virus (DENV), zika virus (ZIKV), West Nile virus (WNV), Japanese encephalitis virus (JEV) and Chikungunya virus (CHIV). We identified signature molecules and pathways for each virus infection based on omics analyses, and determined 77 drug candidates and 146 proteins for those diseases by using a filtering method. Based on the omics analyses, we analyzed the relationship among drugs, target proteins and the five viruses by projecting the signature molecules onto a human protein-protein interaction network. We have classified the drug candidates according to the degree of target proteins in the protein-protein interaction network for the five infectious diseases.
Assuntos
Reposicionamento de Medicamentos , Genômica , Interações Hospedeiro-Patógeno , Metabolômica , Proteômica , Doenças Transmitidas por Vetores/etiologia , Doenças Transmitidas por Vetores/metabolismo , Animais , Biologia Computacional/métodos , Redes Reguladoras de Genes/efeitos dos fármacos , Genômica/métodos , Interações Hospedeiro-Patógeno/genética , Humanos , Metabolômica/métodos , Proteômica/métodos , Transdução de Sinais/efeitos dos fármacos , Doenças Transmitidas por Vetores/tratamento farmacológicoRESUMO
Mosquito-borne arthropod-borne viruses (arboviruses) such as the dengue virus (DENV), Zika virus (ZIKV), and chikungunya virus (CHIKV) are important human pathogens that are responsible for significant global morbidity and mortality. The recent emergence and re-emergence of mosquito-borne viral diseases (MBVDs) highlight the urgent need for safe and effective vaccines, therapeutics, and vector-control approaches to prevent MBVD outbreaks. In nature, arboviruses circulate between vertebrate hosts and arthropod vectors; therefore, disrupting the virus lifecycle in mosquitoes is a major approach for combating MBVDs. Several strategies were proposed to render mosquitoes that are refractory to arboviral infection, for example, those involving the generation of genetically modified mosquitoes or infection with the symbiotic bacterium Wolbachia. Due to the recent development of high-throughput screening methods, an increasing number of drugs with inhibitory effects on mosquito-borne arboviruses in mammalian cells were identified. These antivirals are useful resources that can impede the circulation of arboviruses between arthropods and humans by either rendering viruses more vulnerable in humans or suppressing viral infection by reducing the expression of host factors in mosquitoes. In this review, we summarize recent advances in small-molecule antiarboviral drugs in mammalian and mosquito cells, and discuss how to use these antivirals to block the transmission of MBVDs.
Assuntos
Aedes/virologia , Antivirais/farmacologia , Infecções por Arbovirus/transmissão , Infecções por Arbovirus/virologia , Arbovírus/efeitos dos fármacos , Mosquitos Vetores/virologia , Aedes/efeitos dos fármacos , Animais , Antivirais/química , Antivirais/uso terapêutico , Infecções por Arbovirus/tratamento farmacológico , Arbovírus/classificação , Células Cultivadas , Descoberta de Drogas/métodos , Avaliação Pré-Clínica de Medicamentos , Humanos , Controle de Mosquitos/métodos , Doenças Transmitidas por Vetores/tratamento farmacológico , Doenças Transmitidas por Vetores/transmissão , Doenças Transmitidas por Vetores/virologia , Replicação Viral/efeitos dos fármacosRESUMO
Efforts to control and eliminate human schistosomiasis have accelerated over the past decade. In a number of endemic countries and settings, interruption of schistosome transmission has been achieved. In others, Schistosoma infections continue to challenge program managers at different levels, from the complexity of the transmission cycle, over limited treatment options and lack of field-friendly accurate diagnostics, to controversy around adequate intervention strategies. We conducted a landscape analysis on parasitic and vector-borne disease elimination approaches with the aim to identify evidence-based strategies, core components and key concepts for achieving and sustaining schistosomiasis control and for progressing elimination efforts towards interruption of transmission in sub-Saharan Africa. A total of 118 relevant publications were identified from Web of Science, Pubmed and the grey literature and reviewed for their content. In addition, we conducted in-depth interviews with 23 epidemiologists, program managers, policymakers, donors and field researchers. Available evidence emphasizes the need for comprehensive, multipronged and long-term strategies consisting of multiple complementary interventions that must be sustained over time by political commitment and adequate funding in order to reach interruption of transmission. Based on the findings of this landscape analysis, we propose a comprehensive set of intervention strategies for schistosomiasis control and elimination. Before deployment, the proposed interventions will require review, evaluation and validation in the frame of an expert consultation as a step towards adaptation to specific contexts, conditions and settings. Field testing to ensure local relevance and effectiveness is paramount given the diversity of socio-ecological and epidemiological contexts.
Assuntos
Esquistossomose/prevenção & controle , Doenças Transmitidas por Vetores/prevenção & controle , África Subsaariana/epidemiologia , Animais , Erradicação de Doenças , Vetores de Doenças , Humanos , Higiene , Esquistossomose/tratamento farmacológico , Esquistossomose/epidemiologia , Esquistossomose/transmissão , Caramujos/crescimento & desenvolvimento , Caramujos/parasitologia , Doenças Transmitidas por Vetores/tratamento farmacológico , Doenças Transmitidas por Vetores/epidemiologia , Doenças Transmitidas por Vetores/transmissãoRESUMO
Covering: up to 2019 Secondary metabolites of microbial origin have long been acknowledged as medically relevant, but their full potential remains largely unexploited. Of the countless natural compounds discovered thus far, only 5-10% have been isolated from microorganisms. At the same time, while whole-genome sequencing has demonstrated that bacteria and fungi often encode natural products, only a few genera have yet been mined for new compounds. This review explores the contributions of bacterial natural products to combatting infection by malaria parasites, filarial worms, and arboviruses such as dengue, Zika, Chikungunya, and West Nile. It highlights how molecules isolated from microorganisms ranging from marine cyanobacteria to mosquito endosymbionts can be exploited as antimicrobials and antivirals. Pursuit of this mostly untapped source of chemical entities will potentially result in new interventions against these tropical diseases, which are urgently needed to combat the increase in the incidence of resistance.